Thromb Haemost
DOI: 10.1055/a-2348-5697
Michael Hristov
1
Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten (IPEK), Ludwig-Maximilians-Universität (LMU), München, Germany
,
Christian Weber
1
Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten (IPEK), Ludwig-Maximilians-Universität (LMU), München, Germany
2
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), München, Germany
3
Munich Cluster for Systems Neurology (SyNergy), München, Germany
4
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands
› Author Affiliations
Funding The authors are supported by the Deutsche Forschungsgemeinschaft (SFB 1123) and the August-Lenz-Stiftung.
![SFX Search]()
Permissions and Reprints
Abstract
Endothelial dysfunctions together with a dysregulated immune response and lipid accumulation are important confounding factors in the onset and chronic development of atherosclerosis. Recently, a large body of data has emerged on the sequential involvement of different immune cell types, including monocytes, in the pathology of this disease. In this condensed review, we aim to highlight some of the recent basic research and clinical findings on monocyte subsets published since our joint European Society of Cardiology consensus document, and re-evaluate their potential relevance as surrogate biomarkers in coronary artery disease.
Keywords
monocytes -
atherosclerosis -
leukocytes -
activation
The review process for this paper was fully handled by Gregory Y. H. Lip, Editor in Chief.
Publication History
Received: 30 April 2024
Accepted: 18 June 2024
Accepted Manuscript online:
19 June 2024
Article published online:
06 July 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Stuttgart · New York
References
1
Weber C,
Noels H.
Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17 (11) 1410-1422
2
Weber C,
Shantsila E,
Hristov M.
et al.
Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups “Atherosclerosis & Vascular Biology” and “Thrombosis”. Thromb Haemost 2016; 116 (04) 626-637
3
Auffray C,
Sieweke MH,
Geissmann F.
Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692
4
Shi C,
Pamer EG.
Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11 (11) 762-774
5
Ruder AV,
Wetzels SMW,
Temmerman L,
Biessen EAL,
Goossens P.
Monocyte heterogeneity in cardiovascular disease. Cardiovasc Res 2023; 119 (11) 2033-2045
6
Cros J,
Cagnard N,
Woollard K.
et al.
Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33 (03) 375-386
7
Ziegler-Heitbrock L,
Ancuta P,
Crowe S.
et al.
Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116 (16) e74-e80
8
Wong KL,
Tai JJ,
Wong WC.
et al.
Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011; 118 (05) e16-e31
9
Zawada AM,
Rogacev KS,
Rotter B.
et al.
SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118 (12) e50-e61
10
Shantsila E,
Wrigley B,
Tapp L.
et al.
Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost 2011; 9 (05) 1056-1066
11
Zawada AM,
Zhang L,
Emrich IE.
et al.
MicroRNA profiling of human intermediate monocytes. Immunobiology 2017; 222 (03) 587-596
12
Hamers AAJ,
Dinh HQ,
Thomas GD.
et al.
Human monocyte heterogeneity as revealed by high-dimensional mass cytometry. Arterioscler Thromb Vasc Biol 2019; 39 (01) 25-36
13
Wildgruber M,
Lee H,
Chudnovskiy A.
et al.
Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One 2009; 4 (05) e5663
14
Tak T,
Drylewicz J,
Conemans L.
et al.
Circulatory and maturation kinetics of human monocyte subsets in vivo. Blood 2017; 130 (12) 1474-1477
15
Mandl M,
Schmitz S,
Weber C,
Hristov M.
Characterization of the CD14++CD16+ monocyte population in human bone marrow. PLoS One 2014; 9 (11) e112140
16
Madjid M,
Awan I,
Willerson JT,
Casscells SW.
Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44 (10) 1945-1956
17
Fukuda D,
Shimada K,
Tanaka A,
Kawarabayashi T,
Yoshiyama M,
Yoshikawa J.
Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004; 43 (01) 18-23
18
Shantsila E,
Ghattas A,
Griffiths HR,
Lip GYH.
Mon2 predicts poor outcome in ST-elevation myocardial infarction. J Intern Med 2019; 285 (03) 301-316
19
Abo-Aly M,
Shokri E,
Chelvarajan L,
Tarhuni WM,
Tripathi H,
Abdel-Latif A.
Prognostic significance of activated monocytes in patients with ST-elevation myocardial infarction. Int J Mol Sci 2023; 24 (14) 11342
20
Boidin M,
Lip GYH,
Shantsila A,
Thijssen D,
Shantsila E.
Dynamic changes of monocytes subsets predict major adverse cardiovascular events and left ventricular function after STEMI. Sci Rep 2023; 13 (01) 48
21
Foster GA,
Gower RM,
Stanhope KL,
Havel PJ,
Simon SI,
Armstrong EJ.
On-chip phenotypic analysis of inflammatory monocytes in atherogenesis and myocardial infarction. Proc Natl Acad Sci U S A 2013; 110 (34) 13944-13949
22
Yamamoto H,
Yoshida N,
Shinke T.
et al.
Impact of CD14++CD16+ monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients. Atherosclerosis 2018; 269: 245-251
23
Lo SC,
Lee WJ,
Chen CY,
Lee BC.
Intermediate CD14++CD16+ monocyte predicts severe coronary stenosis and extensive plaque involvement in asymptomatic individuals. Int J Cardiovasc Imaging 2017; 33 (08) 1223-1236
24
Merinopoulos I,
Bhalraam U,
Holmes T.
et al.
Circulating intermediate monocytes CD14++CD16+ are increased after elective percutaneous coronary intervention. PLoS One 2023; 18 (12) e0294746
25
Rogacev KS,
Cremers B,
Zawada AM.
et al.
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60 (16) 1512-1520
26
Arnold KA,
Blair JE,
Paul JD,
Shah AP,
Nathan S,
Alenghat FJ.
Monocyte and macrophage subtypes as paired cell biomarkers for coronary artery disease. Exp Physiol 2019; 104 (09) 1343-1352
27
Markofski MM,
Flynn MG.
Elevated circulating CD16+ monocytes and TLR4+ monocytes in older adults with multiple cardiometabolic disease risk factors. Exp Gerontol 2021; 154: 111530
28
Krychtiuk KA,
Lenz M,
Hohensinner P.
et al.
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. J Clin Lipidol 2021; 15 (03) 512-521
29
Williams EL,
Stimpson ML,
Lait PJP.
et al.
Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14++ CD16+ intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype. Br J Haematol 2021; 192 (02) 375-384
30
Graff RM,
Kunz HE,
Agha NH.
et al.
β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav Immun 2018; 74: 143-153
31
Rutkowska-Zapała M,
Suski M,
Szatanek R.
et al.
Human monocyte subsets exhibit divergent angiotensin I-converting activity. Clin Exp Immunol 2015; 181 (01) 126-132
32
Thaler B,
Hohensinner PJ,
Krychtiuk KA.
et al.
Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans. Sci Rep 2016; 6: 30162
留言 (0)